ETFs Are Net Sellers of Revvity (RVTY) on Oct. 28
This article first appeared on GuruFocus.
Fifteen ETFs were buying Revvity (RVTY) versus 8 selling in Wednesday’s session, but the sellers outweighed the buyers by dollar value, producing a net outflow of $28.0 million. More funds traded the other way, though in smaller amounts. The move extended a four-day streak of net selling, following net outflows of $0.1 million on Oct. 27, $0.3 million on Oct. 26 and $0.7 million on Oct. 23. Before that, ETF flows were slightly positive at $0.2 million on Oct. 22.
Every ETF and guru trade in RVTY is tracked on the RVTY guru trades page.
Which ETFs sold RVTY on Wednesday?
The largest sellers by dollar value were DFSV ($32.6 million), RSPH ($0.1 million) and XLV ($0.0 million). In all, 15 ETFs added shares and 8 cut them.
DFSV drove the day’s ETF activity, cutting 197,185 shares for a $32.6 million reduction, a 48.74% drop in its stake, with the position at a 0.13% weight. RSPH trimmed 539 shares for $0.1 million, a 0.45% stake change at a 2.04% weight, while XLV, IWB, SPYM, IWS and EFIV posted only fractional reductions. SNPE added 10 shares. Revvity sits in the Healthcare sector’s Diagnostics & Research industry with a market cap of $18.5 billion.
Have ETFs been buying or selling RVTY lately?
Over the last 5 reported days, ETFs were net buyers on 1 and net sellers on 4, so the recent trend is mostly selling.
What does RVTY do?
Revvity Inc. is a global life sciences and diagnostics company headquartered in Waltham, Massachusetts, formed in 2023 when PerkinElmer rebranded its life sciences and diagnostics businesses following the divestiture of its applied markets segment.
Revvity reported trailing-12-month revenue of $2.91 billion, up 11.0% year over year, with a gross margin of 48.2% and a net margin of 8.2%. Its P/E is 78.72, P/B 2.56 and P/S 6.43, against a market cap of $18.5 billion. The GF Score is 70, and the GF Value of $117.49 compares with a price of $165.78. The dividend yield is 0.2%, and the stock is up 71.77% year to date.